114 FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION. (April 2015)